Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe

BMC Cancer

Table 4 Incremental benefit of a boys and girls vaccination strategy against HPV 6,11,16,18 vs. girls-only vaccination (results presented in a steady state situation, at 50 and 100 years; results from base case analysis)

Gender	Disease	Annual number of HPV 6/11/16/18 cases	Annual number of cases avoided with girls only vaccination		Incremental number of cases avoided due to GNV (vs. girls only)		Relative reduction in remaining burden: GNV vs. girls only (%)
Gender	Disease	Annual number of HPV 6/11/16/18 cases	At 50 years	At 100 years	At 50 years	At 100 years	At 50 years	At 100 years
Female	Genital warts	288,959	227,388	228,724	34,936	35,164	−56.7	−58.4
	Cervical cancer	23,254	13,848	19,728	958	1,362	−10.2	−38.6
	Vulvar cancer	2,702	873	2,286	67	157	−3.7	−37.8
	Vaginal cancer	1,146	406	981	31	66	−4.2	−39.9
	Anal cancer	2,929	821	2,330	80	258	−3.8	−43.0
	Head/neck cancer	2,531	701	2,020	67	220	−3.7	−43.0
	Total cancers	32,562	16,649	27,345	1,203	2,062	−7.6	−39.5
Male	Genital warts	325,722	202,671	202,587	85,740	87,900	−69.7	−71.4
	Penile cancers	1,091	93	197	156	542	−15.6	−60.6
	Anal cancers	1,699	313	1,067	180	402	−13.0	−63.6
	Head/neck cancers	12,707	2,555	8,203	1,449	2,967	−14.3	−65.9
	Total cancers	15,497	2,961	9,467	1,784	3,911	−14.2	−64.9
Female + Male	Genital warts	614,681	430,059	431,311	120,676	123,064	−65.4	−67.1
Female + Male	Total cancers	48,059	19,610	36,812	2,987	5,973	−10.5	−53.1

GNV, gender-neutral vaccination (boys and girls vaccination); HPV, human papillomavirus.

ISSN: 1471-2407